Editorial Board member, Eleni Andreopoulou, spoke to us at the 2019 ASCO annual meeting about the advances made in immunotherapy for the treatment of breast cancer.
In Part 1 Eleni discusses the rationale and evidence that supports the use of immune checkpoint inhibitors.
Questions
1. What is the rationale for the use of immune checkpoint inhibitors in breast cancer, which has historically been viewed as not immunogenic? (0:04)
2. What clinical evidence supports the use of immune checkpoint inhibitors in early stage and metastatic breast cancer? (1:28)
Speaker disclosure: Eleni Andreopoulou has nothing to disclosure in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
